Biopharmaceuticals

Road to Elimination: Barriers and Best Practices in Hepatitis C Management

Boston Consulting Group

Over the last five years, new antiviral therapies have been introduced to patients with the hepatitis C virus (HCV) that in many cases cure the disease. And for the first time, there is a global common goal: the elimination of viral hepatitis as a public health threat. Although the tools are available to eliminate HCV, there are still gaps in ensuring universal access to prevention, care, and treatment. This new report from BCG in collaboration with leading HCV researchers and advocates addresses the barriers that are impeding progress toward eliminating hepatitis C, and provides suggestions to overcome them based on the best practices identified in different countries in Europe and Australia.

Biopharmaceuticals